Inflection Biosciences’ panel of advisors, comprising leading physicians and scientific leaders in the field of oncology along with technical, business and regulatory experts, has been assembled to strategically support development of the company’s innovative pipeline.

Dr Martin Page has over 30 years experience in Oncology R&D within Biotech and Pharmaceutical companies. From 2005-2011 he worked for Johnson & Johnson Pharmaceuticals where he was Vice President, Global Head of Oncology Research managing the small molecule and monoclonal antibody pipelines across Europe and USA. Prior to this he was Senior Director of Cancer Biology at OSI Pharmaceuticals, Director of Biology at Oxford GlycoSciences, and Oncology Therapeutic Head for Europe in Glaxo-Wellcome. Through his leadership, Martin has taken multiple Oncology preclinical IND candidates into clinical trials. In addition to managing Oncology R&D pipelines, Martin understands and deploys the integration of Translational Research and Biomarker technologies into their Development paths. Since 2011 he has taken a new role as an independent Oncology Scientific Consultant working with investment/venture capital companies, Biotechs and CROs.


Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2019 Inflection Biosciences.   Web Design by Webtrade